BAX

Baxter International Inc. Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Baxter International Inc. operates in three primary segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The company is currently navigating the post-divestiture landscape following the January 2025 sale of its Kidney Care business (now Vantive Health LLC) and managing ongoing operational challenges related to the Novum IQ Large Volume Pump (Novum LVP) Class I recall.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Decline: The company reported a net loss of $15 million compared to net income of $126 million in Q1 2025. This shift is primarily due to the absence of the $62 million gain on the sale of the Kidney Care business recorded in the prior year (classified as discontinued operations) and increased special items.
• Revenue Growth: Net sales increased 3% year-over-year to $2.701 billion. However, organic sales growth was flat (-1%) due to a 4% decline in U.S. sales, partially offset by a 12% increase in international sales driven by favorable foreign exchange rates.
• Segment Performance:
  • Medical Products & Therapies: Sales up 2% ($1.285B), but operating income fell 24% to $186 million due to lower Novum LVP volumes and higher costs.
  • Healthcare Systems & Technologies: Sales flat ($705M); operating income dropped 29% to $66 million.
  • Pharmaceuticals: Sales up 7% ($621M) driven by Drug Compounding growth, though Injectables & Anesthesia declined 10%.
• Special Items: Special items adversely impacted net income by $205 million in Q1 2026, including $68 million in business optimization charges (restructuring) and $11 million in separation-related costs.

Guidance, Outlook, and Risks

• Novum LVP Recall: The company maintains a voluntary shipment and installation hold on the Novum LVP in the U.S. and Canada. Management expects no meaningful sales from this product while the hold is in effect. Estimates for remediation costs were adjusted in Q1 2026 but were not material.
• Business Optimization: Baxter continues restructuring to mitigate dis-synergies from the Kidney Care sale. An additional $2 million in pre-tax cash costs is expected for ongoing initiatives.
• Macroeconomic Factors: Results are adversely impacted by tariffs, inflation, and supply chain constraints. The company has submitted refund requests for certain tariffs but has not recorded an asset for potential refunds due to uncertainty.
• Credit Ratings: Standard & Poor's and Moody's revised the company's credit outlook from "Stable" to "Negative" in Q1 2026.
• Legal Contingencies: Significant litigation includes class actions regarding the Novum LVP, antitrust claims against Hillrom, and DOJ investigations into False Claims Act compliance. Total legal reserves were $44 million as of March 31, 2026.
• Dividends: The quarterly dividend was reduced to $0.01 per share in Q1 2026, down from $0.17 in Q1 2025.

Investor Verification Checklist

• Novum LVP Resolution: Verify the timeline for lifting the shipment/installation hold and the final cost of remediation and warranty claims.
• Restructuring Progress: Monitor the execution of business optimization charges and the realization of cost savings to offset dis-synergies from the Kidney Care divestiture.
• Tariff Refunds: Track the status of tariff refund claims and the potential impact of Section 122 duties on future margins.
• Credit Outlook: Assess the implications of the "Negative" credit outlook revision on borrowing costs and covenant compliance.
• Legal Exposure: Review developments in the Novum LVP securities class actions and the DOJ investigations regarding Hillrom and IV flexible containers.